Article

Direct Oral Anticoagulants: Assessing Clinical and Economic Value

https://www.pharmacytimes.org/landing/1087

https://www.pharmacytimes.org/landing/1087

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Amir Fathi, MD, Massachusetts General Hospital
Related Content
The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com
August 14th 2025

Predictive Model Forecasts Advanced NSCLC Outcomes

Jared Kaltwasser
managed care cast banner
August 14th 2025

Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD

Mary Caffrey Skylar Jeremias Joseph Mikhael, MD
Myasthenia Gravis | Image Credit: © Richelle - stock.adobe.com
August 14th 2025

Even Low Disease Activity Has QOL Impact in Myasthenia Gravis

Maggie L. Shaw
AJMC podcast banner
August 14th 2025

What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD

Hayden E. Klein Skylar Jeremias Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
traffic-related air pollution | Sergiy Serdyuk - stock.adobe.com
August 14th 2025

Air Pollution, Genes Together Raise Psoriasis Risk, Study Finds

Pearl Steinzor
Diabetes monitoring | Image credit: abidika - stock.adobe.com
August 14th 2025

Technology Improves Glycemic Control in Type 1 Diabetes, but Disparities Widen

Pearl Steinzor

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo